Showing results (91-100 of 279) with videos related to
Sort By:
Pageof 28
Metabolites|September 23, 2022
Influence of Genetic West African Ancestry on Metabolomics among Hypertensive PatientsMai Mehanna, Caitrin W McDonough, Steven M Smith, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 7, 2016
Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progressionMartin Pejchinovski, Justyna Siwy, Jochen Metzger, et al.Journal of the American Society of Nephrology : JASN|April 23, 2021
The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 TrialJudith E Heida, Ron T Gansevoort, Vicente E Torres, et al.Journal of Hypertension|November 10, 2017
Protein kinase Cα deletion causes hypotension and decreased vascular contractilityBrandi M Wynne, Cameron G McCarthy, Theodora Szasz, et al.Clinical Journal of the American Society of Nephrology : CJASN|December 30, 2020
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.Clinical and Translational Science|May 15, 2024
Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockersMai Mehanna, Caitrin W McDonough, Steven M Smith, et al.Seminars in Nephrology|July 16, 2025
Educating the Next-Generation Expert in Nephrology GeneticsMatthew B Lanktree, Shaymaa Shurrab, Resham Ejaz, et al.Kidney International|June 18, 2010
Renal CD14 expression correlates with the progression of cystic kidney diseaseJuling Zhou, Xiaosen Ouyang, Xiangqin Cui, et al.American Journal of Nephrology|February 7, 2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Olivier Devuyst, Arlene B Chapman, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 6, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.Pageof 28